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Introduction
Anti-Retroviral Therapy (ART) has dramatically reduced
morbidity and mortality associated with HIV/AIDS. How-
ever, this has left a niche for the emergence of liver disease
in HIV-positive individuals co-infected with HBV. Despite
the geographical overlap between highly endemic HBV
and HIV in Southern Africa, there is a wide range in the
prevalence of co-infection. We therefore set out to charac-
terize the epidemiology of HIV/HBV co-infection in a
Durban cohort, and to investigate the possible impact of
HBV infection on HIV disease progression.
Materials and methods
We investigated a cohort of 498 adult women recruited via
antenatal/postnatal clinics in Durban, South Africa, of
whom 72 were HIV negative and 426 were chronically
HIV-infected and ART-naïve (median CD4 count 368
cells/mm3, median HIV-1 RNA load 4.47 log10 copies/
ml). We screened plasma for HBsAg by ELISA (Biokit).
CD8+ T cell responses to HIV peptides were quantified by
IFN-gamma ELISpot assay in 325 HIV-infected individuals
including 35 with HBV coinfection.
Results
Overall HBsAg prevalence was 46/498 (9.2%; 95%-confi-
dence interval 7-12%); coinfection rates were 9.4% in HIV-
positive and 8.3% in HIV-negative individuals. CD4 counts
were significantly lower in with HBV/HIV coinfection
than with HIV monoinfection (302 vs. 375 cells/mm3;
p=0.02). However, HBV status made no significant impact
on HIV viral load (4.49 log10 copies/ml in coinfection vs.
4.46 log10 in monoinfection). There was no difference in
breadth, magnitude, or protein-specificity of IFN-gamma
responses to HIV according to HBV status.
Conclusions
In this cohort of Durban women, 9% were coinfected with
HBV. Women with HIV/HBV co-infection had signifi-
cantly lower CD4 counts, highlighting the potential detri-
ment of coinfection. However, in a small subset we did
not find a difference in CD8+ T cell responses to HIV.
These data contribute towards an improved understanding
of the scale of the HIV/HBV coinfection problem in
Africa, and suggest that adverse outcomes are mediated by
factors other than CD8+ T cell responses to HIV.
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